<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844008</url>
  </required_header>
  <id_info>
    <org_study_id>PID 15065</org_study_id>
    <nct_id>NCT04844008</nct_id>
  </id_info>
  <brief_title>Do Nanobubbles Improve Joint Hypoxia?</brief_title>
  <official_title>An Investigation of Whether Orally Delivered Nanobubbles Have a Physiological Effect on Joint Hypoxia?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflamed joints in patients with rheumatoid arthritis and psoriatic arthritis are&#xD;
      characterized by low oxygen levels and inflammation. We propose to investigate whether tiny&#xD;
      bubbles (nanobubbles) when given in a drink can alter oxygen level in joints. These&#xD;
      nanobubbles are so small that they can enter the bloodstream when given as a drink. This&#xD;
      information will give new information on the role of oxygen in joint inflammation and could&#xD;
      possibly lead to new treatment approaches in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Synovial fluid pO2</measure>
    <time_frame>Change in synovial fluid pO2 between day 1 and day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hypoxia-inducible factor 1α (HIF-1α) protein levels in synovial tissues</measure>
    <time_frame>Change in hypoxia-inducible factor 1α (HIF-1α) protein between day 1 and day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (C)</measure>
    <time_frame>Day28</time_frame>
    <description>Validated PRO assessing: side effects, effectiveness, convenience and global satisfaction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in the absolute and relative cell count in synovial fluid and synovial biopsy</measure>
    <time_frame>day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline of synovial fibroblast protein expression</measure>
    <time_frame>day 28</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Nanobubble</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sports drink nanobubble drink</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Flavoured drink- no active ingredients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nanobubble drink</intervention_name>
    <description>Commercially available sports drink</description>
    <arm_group_label>Nanobubble</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Participant is willing and able to give informed consent for participation in the&#xD;
             study.&#xD;
&#xD;
               -  Male or Female, aged 18 years or above.&#xD;
&#xD;
               -  Fulfil American College of Rheumatology/European League Against Rheumatism&#xD;
                  criteria (ACR/EULAR) 2010 Rheumatoid Arthritis Classification Criteria or fulfil&#xD;
                  Classification Criteria for Psoriatic Arthritis 2006 (CASPAR).&#xD;
&#xD;
               -  Selected joint for biopsy must be minimum Grade 2 synovial thickening for large&#xD;
                  joint (knee) and medium joint (wrist), or minimum Grade 3 synovial thickening for&#xD;
                  small joint (metacarpophalangeal).&#xD;
&#xD;
               -  Women of child bearing potential who are willing to use effective contraception&#xD;
                  (i.e. barrier, oral contraceptive pill, implanted contraception, or previous&#xD;
                  hysterectomy, bilateral oophorectomy) for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Currently on oxygen therapy.&#xD;
&#xD;
               -  Current enrolment in any other clinical study involving an investigational study&#xD;
                  treatment.&#xD;
&#xD;
               -  Pregnant or lactating, or women planning to become pregnant or initiating&#xD;
                  breastfeeding.&#xD;
&#xD;
               -  Intramuscular, intravenous or intra-articular administration of corticosteroid&#xD;
                  within 4 weeks prior to baseline visit.&#xD;
&#xD;
               -  Oral corticosteroid &gt; 10 mg/day prednisolone or equivalent within 4 weeks prior&#xD;
                  to baseline visit.&#xD;
&#xD;
               -  Oral corticosteroid dose not stable for at least 4 weeks prior to baseline visit.&#xD;
&#xD;
               -  Oral non-steroidal anti-inflammatory drugs (including aspirin &gt; 75 mg/ day and&#xD;
                  selective-cyclooxygenase inhibitors) dose not stable for at least 4 weeks prior&#xD;
                  to baseline visit.&#xD;
&#xD;
               -  Disease modifying anti-rheumatic drugs (DMARDs) dose not stable for at least 4&#xD;
                  weeks prior to baseline visit.&#xD;
&#xD;
               -  History of septic arthritis.&#xD;
&#xD;
               -  Participants on warfarin, heparin, low molecular weight heparin, direct oral&#xD;
                  anticoagulants. Oral anti-platelet agents are permitted.&#xD;
&#xD;
               -  History of haemophilia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Duncan Richards, DM</last_name>
    <phone>01865 737882</phone>
    <email>duncan.richards@ndorms.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shing Law</last_name>
      <phone>01865737882</phone>
      <email>Shing.law@ndorms.ox.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

